Close Menu
April 23, 2019

AMP/ACMG/CAP Cancer Sequence Variant Guidelines: A Two-Year Status Report

Genome Webinar

Clinical Director, Molecular Tumor Board & Medical Director, Gastrointestinal Cancers, Inova Medical Group

Professor of Pediatrics and Professor of Clinical Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine

Chief Scientific Officer, N-of-One, a Qiagen Company

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. Upon the release of these guidelines, several laboratories and molecular diagnostic decision-support companies incorporated them into their reporting to give pathologists and treating oncologists a more consistent report format that clearly conveys the level of importance and evidence for each variant, enabling them to provide the most relevant treatment options for oncology patients.

In this webinar, Dr. Timothy Cannon, Medical Director for Gastrointestinal Cancers at Inova Medical Group, Dr. Marilyn Li, Vice Chief of the Division of Genomic Diagnostics at Children’s Hospital of Philadelphia, and Dr. Sheryl Elkin, CSO of N-of-One, a Qiagen company, discuss adoption of the guidelines in the field to date, what’s working, and any new challenges/opportunities that have come from the initial launch.

Attendees can expect to learn about some of the complexities that exist in incorporating the AMP guidelines into treatment strategies, as well as what might be on the horizon in industry standardization for levels of evidence.